SAN FRANCISCO (Reuters)—With a backlash brewing over the price of medicines in the U.S., drugmakers are pushing back with a new message: Most people don’t pay retail. Top executives from Eli Lilly and Co, Merck & Co and Biogen Inc. said in interviews with Reuters this week that the media focus on retail, or “list…
Survey Highlights High Out-of-pocket Costs for RA Care
The “RA in America 2013″ survey estimates out-of-pocket cost for RA treatment at $1,000 to $5,000 per year. (posted Oct. 25)